Article Link: FDA Approves Endari (L-glutamine oral powder) for Sickle Cell Disease Source: FDA New Drug Approvals
Bristol-Myers Squibb’s Orencia (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults
Article Link: Bristol-Myers Squibb’s Orencia (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults ...
Arbor Pharmaceuticals, LLC Announces FDA Approval for Triptodur (triptorelin)
Article Link: Arbor Pharmaceuticals, LLC Announces FDA Approval for Triptodur (triptorelin) Source: FDA New Drug Approvals
FDA Approves Vectibix (panitumumab) for Use in Wild-Type RAS Metastatic Colorectal Cancer
Article Link: FDA Approves Vectibix (panitumumab) for Use in Wild-Type RAS Metastatic Colorectal Cancer Source: FDA New Dru...
FDA Approves Bevyxxa (betrixaban) for Hospital and Extended Duration Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients
Article Link: FDA Approves Bevyxxa (betrixaban) for Hospital and Extended Duration Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical P...
FDA Approves Haegarda – First Subcutaneous C1 Esterase Inhibitor for Hereditary Angioedema
Article Link: FDA Approves Haegarda – First Subcutaneous C1 Esterase Inhibitor for Hereditary Angioedema Source: FDA ...
FDA Approves Rituxan Hycela (rituximab and hyaluronidase human) for Subcutaneous Injection in Certain Blood Cancers
Article Link: FDA Approves Rituxan Hycela (rituximab and hyaluronidase human) for Subcutaneous Injection in Certain Blood Cancers ...
FDA Approves Mydayis (mixed salts of a single-entity amphetamine product) – A New Once-Daily Option for ADHD
Article Link: FDA Approves Mydayis (mixed salts of a single-entity amphetamine product) – A New Once-Daily Option for ADHD ...
Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
Article Link: Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Tre...
Melinta Therapeutics Announces FDA Approval of Baxdela (delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Article Link: Melinta Therapeutics Announces FDA Approval of Baxdela (delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)�...
